Cancer risk in immune-mediated inflammatory diseases (IMID)

Molecular Cancer

Review

Manuelle Viguier¹  Rudi Beyaert²  Lieve Brochez³  Hans Prenen⁴  Laurent Beaugerie⁵  Gert Van Assche⁶  Jean-Pascal Machiels⁷  Veronique Cocquyt⁸  Guy Jerusalem⁹  Filip De Keyser^1,10  Edouard Louis^1,11  Jean-Christophe Renauld^1,12  Pierre Masson^1,13 

[1] Assistance-Publique-Hôpitaux de Paris, Paris, France;Dermatology department, Université Paris VII Denis-Diderot, Hôpital Saint-Louis, Paris, France;Department of Biomedical Molecular Biology, Ghent University, Ghent, VIB, Belgium;Department of Molecular Biomedical Research, Ghent University, Ghent, VIB, Belgium;Department of Dermatology, Ghent University Hospital, Ghent, Belgium;Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium;Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine, F-75012, Paris, France;UPMC Univ Paris, 06 F-75005, Paris, France;Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium;Department of Medical Oncology Unit, Université Catholique de Louvain, Brussels, Belgium;Cliniques Universitaires Saint-Luc, Brussels, Belgium;Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium;Department of Medical Oncology, University of Liège, Liège, Belgium;Department of Rheumatology, Ghent University, 0K12, De Pintelaan 185, B-9000, Ghent, Belgium;Gastroenterology, CHU and University of Liege, Liège, Belgium;Ludwig Institute for Cancer Research and Experimental Medicine Unit, Université Catholique de Louvain, Brussels, Belgium;de Duve Institute, Université Catholique de Louvain, Brussels, Belgium;

关键词: Antirheumatic agents;    Autoimmune diseases;    Biological products;    Cancer;    Inflammation;    Tumor necrosis factor;   

DOI  :  10.1186/1476-4598-12-98

 received in 2013-04-23, accepted in 2013-08-22,  发布年份 2013

来源: Springer

【 摘 要 】

Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history.This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.

【 授权许可】

Unknown   
© Beyaert et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.